Robert R. LaBadie
Biography
Robert R LaBadie is a researcher in Pfizer Inc, New York, NY, USA .Currently his latest research interest is on the field of Background and Objective Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Lorlatinib is metabolized by cytochrome P450 (CYP) 3A and contraindicated with strong CYP3A inducers